HYDERABAD: A Significant Shift in Vaccine Development

In a surprising turn of events, Auro Vaccines Pvt Ltd, a subsidiary of Aurobindo Pharma, has terminated its licensing agreement with Hilleman Laboratories Singapore Pte Ltd. This partnership, initiated in September 2023, was aimed at developing, manufacturing, and commercializing a pediatric pentavalent vaccine candidate.

The termination, effective March 5, 2025, was disclosed by Aurobindo Pharma in a regulatory filing. The company emphasized that this decision is not expected to have a material impact on its operations or financials, as Auro Vaccines is not considered a material subsidiary. The agreement had stipulated milestone payments and royalties to Hilleman Labs upon achieving certain development and clinical study outcomes, as well as upon commercialization of the vaccine candidate.

Despite the early stage of the vaccine asset, Aurobindo Pharma assures stakeholders that the termination will not significantly affect the company or its subsidiaries. The company commits to informing the exchanges and providing necessary disclosures should there be any significant impact in the future.